New York-based Bristol-Myers Squibb (NYSE: BMY) and development partner AstraZeneca (NYSE: AZN) released data from several studies at the 71st American Diabetes Association Scientific Sessions in San Diego. In a Phase 3 extension study, the investigational compound dapagliflozin plus metformin produced sustained gylcemic control and weight reduction in patients with Type 2 diabetes. In a longer-term, Phase 3 study, the same combination sustained reductions of blood-sugar levels from 52 weeks to 104 weeks, when compared to a commonly used sulphonylurea treatment. The companies also released data from two 24-week studies showing that that dapagliflozin plus metformin XR significantly reduced blood sugar levels compared to dapagliflozin or metformin XR alone plus placebo. Dapagliflozin is currently under review at the FDA, which is expected to hand down a decision by October 28.